| Date |
Title |
Rating |
| 2011-06-30 |
Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia |
None |
| 2011-06-30 |
Auxilium reports three year data from XIAFLEX CORDLESS study in Dupuytren's contracture |
5 |
| 2011-06-30 |
PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint |
None |
| 2011-06-30 |
Positive final results from Medicago's H5N1 Avian Influenza VLP vaccine Phase II trial |
None |
| 2011-06-30 |
Novartis reports NVA237 Phase III trial results against COPD |
None |
| 2011-06-30 |
Conference examines lagging ethical guidelines in face of expanding clinical trials in developing countries |
None |
| 2011-06-30 |
Provectus presents additional data on PV-10 at two separate melanoma conferences |
None |
| 2011-06-29 |
Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing |
None |
| 2011-06-29 |
Zalicus commences Synavive SYNERGY Phase 2b clinical trial for rheumatoid arthritis |
None |
| 2011-06-29 |
Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET |
None |
| 2011-06-29 |
USPTO awards patent for key therapeutic ingredient in CNVN202 targeted molecular cancer therapy |
None |
| 2011-06-29 |
Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness |
None |
| 2011-06-29 |
Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet |
None |
| 2011-06-29 |
Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema |
None |
| 2011-06-29 |
Glybera gene therapy reduces pancreatitis risk in Lipoprotein Lipase Deficiency patients |
None |
| 2011-06-29 |
FDA clears Nuvo's IND for Lidocaine Spray formulation |
None |
| 2011-06-28 |
Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients |
None |
| 2011-06-28 |
FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma |
None |
| 2011-06-28 |
Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction |
2 |
| 2011-06-28 |
BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia |
None |
| 2011-06-28 |
Pfizer to present PF-299 and crizotinib clinical trial data on ALK at WCLC 2011 |
None |
| 2011-06-28 |
Ticagrelor drug with low-dose aspirin effective against acute coronary syndrome |
None |
| 2011-06-28 |
TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011 |
None |
| 2011-06-28 |
Yale University: Gabapentin clinical study on epilepsy may have been a 'seeding trial' |
None |
| 2011-06-28 |
ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint |
None |
| 2011-06-28 |
Researchers, policy experts to examine issue of declining enrollment in clinical trials |
None |
| 2011-06-28 |
Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website |
None |
| 2011-06-28 |
Microbix renegotiates key terms of Hunan influenza vaccine joint venture |
None |
| 2011-06-28 |
Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure |
None |
| 2011-06-28 |
Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis |
None |
| 2011-06-27 |
New and effective diabetes drug seeking approval |
5 |
| 2011-06-27 |
Nile completes dosing in Part B of cenderitide Phase I study for ADHF |
None |
| 2011-06-27 |
Cardium to purchase Transdel's business assets |
None |
| 2011-06-27 |
Positive top line data from Mimetogen MIM-D3 Phase II clinical trial for dry eye disease |
None |
| 2011-06-27 |
Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial |
5 |
| 2011-06-27 |
Genentech, FORMA enter structurally innovative agreement for small molecule cancer program |
None |
| 2011-06-27 |
EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease |
None |
| 2011-06-27 |
FDA responds to EpiCept Ceplene SPA |
None |
| 2011-06-27 |
Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD |
None |
| 2011-06-27 |
Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer |
None |
| 2011-06-27 |
Biota reports preliminary data from CS-8958 Phase III trial against influenza |
None |
| 2011-06-27 |
Positive results from Stealth's Bendavia Phase I renal impairment study |
None |
| 2011-06-27 |
Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011 |
None |
| 2011-06-27 |
New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011 |
4 |
| 2011-06-27 |
Boehringer Ingelheim, Lilly announce new data from linagliptin Phase III study on type 2 diabetes |
5 |
| 2011-06-27 |
New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011 |
3.5 |
| 2011-06-27 |
Promising results from MGH's BCG Phase I trial on type I diabetes |
None |
| 2011-06-27 |
Diabetic patients can benefit from basal insulin analogs |
None |
| 2011-06-27 |
New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011 |
None |
| 2011-06-24 |
PCIB reports main results of Amphinex Phase I/II study against multiple cancers |
None |
| 2011-06-24 |
InVasc commences INV-144 Phase IIa trial in chronic kidney disease |
None |
| 2011-06-24 |
Lithium can prevent aggregation of toxic proteins and cell loss linked with Parkinson's |
None |
| 2011-06-24 |
Nature News examines controversy surrounding Indian HPV vaccine trial |
None |
| 2011-06-24 |
Millennium reports ongoing MLN8237 Phase II study results on non-Hodgkin lymphoma |
None |
| 2011-06-24 |
Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011 |
None |
| 2011-06-24 |
Oxytocin hormone holds promise for children with Prader-Willi syndrome |
None |
| 2011-06-24 |
Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS |
1 |
| 2011-06-24 |
GeoVax opens third clinical trial site for testing HIV/AIDS vaccine |
None |
| 2011-06-24 |
Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer |
None |
| 2011-06-23 |
Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals |
None |
| 2011-06-23 |
FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency |
None |
| 2011-06-23 |
MAP to present LEVADEX data on migraine at 15th Congress of IHC |
None |
| 2011-06-23 |
Positive results from Neurelis NRL-1 Phase I pharmacokinetic study on acute repetitive seizures |
None |
| 2011-06-23 |
Monash researchers receive MMV Project of the Year award for new anti-malarial drug candidate |
None |
| 2011-06-23 |
Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes |
None |
| 2011-06-23 |
Telaprevir drug shows promise in curing hepatitis C infection |
None |
| 2011-06-22 |
Tobira commences cenicriviroc Phase IIb clinical trial for HIV infection |
None |
| 2011-06-22 |
Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder |
None |
| 2011-06-22 |
Naurex commences GLYX-13 Phase II trial in treatment-resistant depression |
None |
| 2011-06-22 |
Multiple abstracts on QNEXA long-term clinical study to be presented at ADA 2011 |
None |
| 2011-06-22 |
Endotis commences EP217609 Phase IIa study in patients undergoing open-heart surgery |
None |
| 2011-06-22 |
Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD |
None |
| 2011-06-22 |
Positive topline results from Lipid Therapeutics LT-02 Phase IIb trial on ulcerative colitis |
None |
| 2011-06-22 |
Medivir initiates TMC649128 phase Ib trial in chronic hepatitis C |
None |
| 2011-06-22 |
Pycnogenol, CoQ10 combination boost heart function |
4 |
| 2011-06-22 |
Results of African malaria vaccine trial expected later this year |
None |
| 2011-06-22 |
CEL-SCI announces results from Multikine Phase II trial on head and neck cancer |
None |
| 2011-06-22 |
Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint |
1 |
| 2011-06-21 |
Seaside Therapeutics commences STX209 Phase 2b study in autism spectrum disorders |
None |
| 2011-06-21 |
DIA recognizes CAPRISA team for outstanding achievement in HIV prevention |
None |
| 2011-06-21 |
Positive results from LCP-Tacro Phase III trial in stable kidney transplant recipients |
None |
| 2011-06-21 |
Lorcaserin Phase 3 trial data on type 2 diabetes to be presented at ADA 2011 |
5 |
| 2011-06-21 |
Halozyme to present three data on Ultrafast Insulin programs at ADA 2011 |
None |
| 2011-06-21 |
Lilly, Boehringer Ingelheim to present new data from diabetes portfolio at ADA scientific sessions |
None |
| 2011-06-21 |
New clinical trial to evaluate safety of tenofovir gel in breastfeeding, pregnant women |
None |
| 2011-06-21 |
Amylin to present data on investigational diabetes drug candidates at ADA annual meeting |
None |
| 2011-06-20 |
Initiation of ALD518/BMS-945429 Phase 2b clinical trial in RA triggers milestone payment to Alder |
None |
| 2011-06-20 |
Spectrum announces various clinical studies on ZEVALIN at ICML 2011 |
None |
| 2011-06-20 |
Concert to advance CTP-499, C-21191 into Phase 2 trials for diabetic nephropathy and spasticity |
5 |
| 2011-06-20 |
GTx commences Capesaris Phase IIb trial in advanced prostate cancer |
None |
| 2011-06-20 |
Alexion begins eculizumab clinical trial in Shiga-toxin producing E. coli hemolytic uremic syndrome |
None |
| 2011-06-20 |
Positive results from vismodegib Phase II study on advanced basal cell carcinoma |
None |
| 2011-06-20 |
Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011 |
None |
| 2011-06-18 |
Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas |
None |
| 2011-06-17 |
Positive data from Ischemix CMX-2043 Phase 2a trial for peri-operative cardiac ischemia-reperfusion injury |
None |
| 2011-06-17 |
Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital |
None |
| 2011-06-17 |
Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL |
None |
| 2011-06-17 |
VIVUS Avanafil phase 3 trial on erectile dysfunction meets primary endpoints |
None |
| 2011-06-17 |
Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma |
None |
| 2011-06-17 |
REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference |
None |
| 2011-06-17 |
Pearl advances PT003 dual combination drug candidate into Phase 2 studies for treatment of COPD |
None |
| 2011-06-17 |
CTI announces positive results from Phase I-II pixantrone combination study against INHL |
None |
| 2011-06-17 |
Experimental vaccine shows promise for patients with newly diagnosed brain tumors |
None |
| 2011-06-17 |
Positive results from etanercept pilot study against dermatomyositis |
None |
| 2011-06-17 |
BioClinica releases new Trident IWR solution |
None |
| 2011-06-16 |
New Australian drug shows positive response in patients with multiple myeloma blood cancer |
2.4 |
| 2011-06-16 |
Adaptimmune melanoma trial opening |
None |
| 2011-06-16 |
Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis |
None |
| 2011-06-16 |
Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia |
None |
| 2011-06-16 |
Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections |
None |
| 2011-06-16 |
Large trial of tenofovir gel for women set to begin in South Africa |
None |
| 2011-06-16 |
Positive results from BiondVax Multimeric-001 Phase IIa trial against influenza |
None |
| 2011-06-16 |
Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists |
None |
| 2011-06-16 |
Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011 |
None |
| 2011-06-16 |
Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings |
None |
| 2011-06-16 |
Provectus PV-10 Phase 2 trial data on metastatic melanoma to be presented at two conferences |
None |
| 2011-06-16 |
Inviragen commences INV21 Phase 1 trial against Hand, Foot and Mouth Disease |
None |
| 2011-06-15 |
Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression |
None |
| 2011-06-15 |
Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID |
None |
| 2011-06-15 |
Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer |
None |
| 2011-06-15 |
immatics initiates IMA901 Phase III trial in renal cell carcinoma |
None |
| 2011-06-15 |
Meda presents new positive results from Dymista Phase-III trial on AR at EAACI 2011 |
None |
| 2011-06-15 |
Sangart commences MP4OX Phase 2b study in acute traumatic injury |
None |
| 2011-06-15 |
Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen |
None |
| 2011-06-15 |
Positive results from Neurelis NRL-01 Phase 1 trial against epilepsy |
None |
| 2011-06-14 |
CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury |
None |
| 2011-06-14 |
The Lancet publishes final 3-year data from landmark HORIZONS-AMI clinical trial |
None |
| 2011-06-14 |
TWi Biotech enrolls over 50% of patients for AC-201 Phase IIb trial against Type II Diabetes |
None |
| 2011-06-14 |
New findings from Deplin clinical trial on major depressive disorder presented at NCDEU |
5 |
| 2011-06-14 |
Orexo completes first OX27 pharmacokinetic trial against breakthrough pain in cancer |
None |
| 2011-06-14 |
GE Healthcare announces results of Optison heart ultrasound contrast agent presented at ASE |
None |
| 2011-06-14 |
FDA approves Cornell Dots for first-in-human clinical trial for treatment of cancer |
None |
| 2011-06-14 |
Cinryze data on hereditary angioedema presented at EAACI 2011 |
None |
| 2011-06-14 |
Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML |
None |
| 2011-06-13 |
Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia |
None |
| 2011-06-13 |
Study reveals positive impact of Soliris on long-term outcomes in PNH patients |
5 |
| 2011-06-13 |
CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary |
None |
| 2011-06-13 |
Trimeris, Synageva enter definitive merger agreement |
None |
| 2011-06-13 |
Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma |
None |
| 2011-06-13 |
Circassia announces ToleroMune vaccine phase II trial results against cat allergy |
None |
| 2011-06-13 |
Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials |
None |
| 2011-06-13 |
Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis |
3 |
| 2011-06-13 |
Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA |
None |
| 2011-06-13 |
Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011 |
None |
| 2011-06-10 |
Preliminary results from Edison's EPI-A0001 28-day phase 2A trial against Friedreich's ataxia |
5 |
| 2011-06-10 |
Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function |
4 |
| 2011-06-10 |
Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011 |
None |
| 2011-06-10 |
FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma |
None |
| 2011-06-10 |
Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting |
None |
| 2011-06-09 |
Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease |
None |
| 2011-06-09 |
Promising results from VX-770 and VX-809 Phase 2 study for cystic fibrosis |
5 |
| 2011-06-09 |
ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme |
None |
| 2011-06-09 |
Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis |
None |
| 2011-06-09 |
TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs |
None |
| 2011-06-09 |
Patient enrollment complete in cilengitide Phase III study against glioblastoma |
3 |
| 2011-06-09 |
Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease |
None |
| 2011-06-09 |
FDA accepts Adamis IND for APC-100 to treat prostate cancer |
None |
| 2011-06-08 |
Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO |
None |
| 2011-06-08 |
Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection |
None |
| 2011-06-08 |
New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA |
None |
| 2011-06-08 |
Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C |
None |
| 2011-06-08 |
Millennium reports results from two VELCADE based combination studies against multiple myeloma |
None |
| 2011-06-08 |
Quest conducts first clinical Investigators Meeting for Oregovomab in Rome, provides corporate updates |
None |
| 2011-06-08 |
Vaccine candidate produces immune response to antigen in all strains of influenza A |
None |
| 2011-06-08 |
Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis |
None |
| 2011-06-08 |
Cabozantinib shows early promise in treatment of prostate cancer spread to the bone |
None |
| 2011-06-08 |
MSU professor to lead acetazolamide clinical trial on idiopathic intracranial hypertension |
None |
| 2011-06-08 |
MicroDose completes atropine inhaler Phase I study on nerve agent poisoning |
None |
| 2011-06-08 |
SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189 |
None |
| 2011-06-08 |
Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne |
None |
| 2011-06-08 |
Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS |
None |
| 2011-06-07 |
Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011 |
None |
| 2011-06-07 |
LLS announces four new Academic Concierge partnerships for cancer drug development |
None |
| 2011-06-07 |
Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences |
None |
| 2011-06-07 |
NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011 |
None |
| 2011-06-07 |
ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011 |
None |
| 2011-06-07 |
AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis |
2 |
| 2011-06-07 |
Unique clinical trial addresses important questions about treating AIDS-related cancers |
None |
| 2011-06-07 |
Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011 |
4 |
| 2011-06-07 |
Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting |
None |
| 2011-06-07 |
FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold |
None |
| 2011-06-07 |
Independent investigators report Lymphoseek meets all endpoints in NEO3-09 Phase 3 study |
None |
| 2011-06-07 |
Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma |
None |
| 2011-06-07 |
Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer |
None |
| 2011-06-07 |
Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint |
None |
| 2011-06-07 |
SPI to commence enrollment in SPI-1005 clinical trial to prevent hearing loss induced by loud music |
None |
| 2011-06-07 |
Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011 |
None |
| 2011-06-07 |
Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011 |
None |
| 2011-06-07 |
VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011 |
None |
| 2011-06-07 |
Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria |
None |
| 2011-06-07 |
Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC |
None |
| 2011-06-07 |
Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011 |
None |
| 2011-06-07 |
Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011 |
None |
| 2011-06-07 |
Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint |
None |
| 2011-06-07 |
Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011 |
4 |
| 2011-06-07 |
Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO |
None |
| 2011-06-06 |
Trifunctional antibody Catumaxomab triggers vaccination effect against cancer |
None |
| 2011-06-06 |
Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year |
None |
| 2011-06-06 |
Encouraging data from Cylene CX-4945 Phase I dose-escalation trial presented at ASCO 2011 |
None |
| 2011-06-06 |
Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer |
None |
| 2011-06-06 |
Astellas to present positive AGS-1C4D4 phase II data in metastatic pancreatic cancer at ASCO 2011 |
None |
| 2011-06-06 |
Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma |
None |
| 2011-06-06 |
Incyte seeks FDA marketing approval of ruxolitinib for myelofibrosis |
None |
| 2011-06-06 |
Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation |
None |
| 2011-06-06 |
Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011 |
None |
| 2011-06-06 |
Amylin's metreleptin clinical study data on partial lipodystrophy presented at ENDO 2011 |
None |
| 2011-06-06 |
Chiasma presents Octreolin pharmacology data from clinical studies at International Pituitary Congress |
None |
| 2011-06-06 |
GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC |
None |
| 2011-06-06 |
United Therapeutics completes oral treprostinil Phase 3 trial on pulmonary arterial hypertension |
None |
| 2011-06-06 |
NCIC CTG's exemestane clinical trial data on breast cancer presented at ASCO 2011 |
None |
| 2011-06-06 |
Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC |
None |
| 2011-06-06 |
Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO |
5 |
| 2011-06-06 |
Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO |
None |
| 2011-06-06 |
New targeted therapy may halt tumor growth in men with advanced prostate cancer |
None |
| 2011-06-06 |
Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO |
5 |
| 2011-06-06 |
Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011 |
None |
| 2011-06-06 |
New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO |
1 |
| 2011-06-06 |
Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint |
None |
| 2011-06-06 |
ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011 |
None |
| 2011-06-06 |
Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011 |
None |
| 2011-06-06 |
Women with breast cancer do not benefit from flaxseed |
None |
| 2011-06-06 |
Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint |
None |
| 2011-06-06 |
Ipsen decides to assess development of Irosustat in combination with hormonal therapies |
None |
| 2011-06-06 |
Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer |
None |
| 2011-06-06 |
ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011 |
None |
| 2011-06-06 |
Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011 |
None |
| 2011-06-06 |
Exemestane reduces risk of breast cancer in high-risk, postmenopausal women |
None |
| 2011-06-06 |
Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma |
None |
| 2011-06-05 |
Ross River Fever vaccine trials begin |
None |
| 2011-06-04 |
Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer |
None |
| 2011-06-04 |
Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011 |
None |
| 2011-06-04 |
Study links loss of PTEN gene with patient's response to melanoma therapy |
None |
| 2011-06-04 |
Impax announces results of IPX066 ADVANCE-PD and APEX-PD Phase III study against Parkinson's |
None |
| 2011-06-04 |
U of A researchers try to combat heart disease in cancer patients |
None |
| 2011-06-04 |
Bionovo's Menerba Phase 2 trial data to be presented at Annual World Congress on Menopause |
5 |
| 2011-06-04 |
Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011 |
None |
| 2011-06-04 |
Researcher to evaluate new approach for treatment of triple-negative breast cancer |
None |
| 2011-06-04 |
Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC |
None |
| 2011-06-04 |
Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma |
None |
| 2011-06-04 |
Nano-formulated indomethacin at lower dose effective in treating pain |
5 |
| 2011-06-04 |
EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011 |
None |
| 2011-06-04 |
Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011 |
None |
| 2011-06-04 |
YM reports updated interim results from CYT387 Phase I/II study on myelofibrosis |
None |
| 2011-06-04 |
Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma |
None |
| 2011-06-04 |
Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer |
None |
| 2011-06-04 |
Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma |
None |
| 2011-06-03 |
Cancer vaccine shows improved response rate in patients |
None |
| 2011-06-03 |
ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011 |
None |
| 2011-06-03 |
ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011 |
None |
| 2011-06-03 |
APC8015F investigational vaccine improves survival of prostate cancer patients |
None |
| 2011-06-03 |
Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men |
5 |
| 2011-06-03 |
Teva completes patient enrollment in COPAXONE Phase III trial for treatment of multiple sclerosis |
None |
| 2011-06-03 |
Angiotensin receptor blockers do not increase risk of cancer: FDA |
None |
| 2011-06-03 |
Positive interim results from iBio's H1N1 influenza subunit vaccine Phase 1 trial |
None |
| 2011-06-03 |
VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers |
None |
| 2011-06-02 |
Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome |
None |
| 2011-06-02 |
Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011 |
None |
| 2011-06-02 |
Positive interim results from Fraunhofer USA CMB's HAC1 influenza vaccine Phase 1 trial |
None |
| 2011-06-02 |
AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011 |
None |
| 2011-06-02 |
Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting |
None |
| 2011-06-02 |
Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab |
None |
| 2011-06-02 |
Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011 |
5 |
| 2011-06-02 |
Anadys receives U.S. patent for setrobuvir to treat chronic hepatitis C |
None |
| 2011-06-02 |
Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia |
None |
| 2011-06-02 |
Fero Industries completes Sucanon human clinical trials on Type-2 diabetes |
None |
| 2011-06-01 |
Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma |
None |
| 2011-06-01 |
Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011 |
5 |
| 2011-06-01 |
Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011 |
None |
| 2011-06-01 |
Diamyd European Phase III study in diabetes does not meet primary endpoint |
None |
| 2011-06-01 |
CrystalGenomics begins enrollment in CG100649 Phase 2b osteoarthritis study |
None |
| 2011-06-01 |
Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease |
None |
| 2011-06-01 |
Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis |
None |